Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 15 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Sodium chloride (0.9%) provides isotonic sodium and chloride ions, expanding extracellular fluid volume via osmotic retention of water. Potassium chloride (0.15%) supplies potassium ions necessary for transmembrane electrochemical gradients, maintenance of cellular membrane potential, and neuromuscular function. Combination corrects hypovolemia and hypokalemia.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion: 500-1000 mL as needed to correct fluid and electrolyte deficits; rate adjusted based on patient's clinical status, typically 1-2 L/day for maintenance. Maximum rate: 20 mEq/h potassium.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable as a pharmacokinetic parameter for electrolyte solutions; the elimination half-life of infused sodium, chloride, and potassium is approximately 2-4 hours, reflecting renal clearance and distribution kinetics. In clinical context, steady-state electrolyte concentrations are achieved within 1-2 hours of continuous infusion.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Sodium and chloride are primarily excreted renally: >90% of filtered sodium and chloride are reabsorbed in the kidneys; excess is excreted in urine. Potassium is mainly excreted renally (approximately 90%), with minor fecal (10%) and negligible biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte